Titan Biotech Ltd Financials
Company Logo

Titan Biotech Ltd Financial Statement

Titan Biotech Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue43.74
Operating Expense34.87
Net Profit5.70
Net Profit Margin13.03
Earning Per Share6.90
EBIDTA8.88
Effective Tax Rate20.52

Titan Biotech Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual164.07
Operating Expenses Annual129.79
Operating Profit Annual36.03
Interest Annual1.17
Depreciation2.84
Net Profit Annual23.66
Tax Annual7.87

Titan Biotech Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning4.86
Cash Flow from Operations21.15
Cash Flow from Investing-20.30
Cash Flow from Financing-2.87
Cash Flow at the End2.84

Titan Biotech Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)21.96
PBIT Margin (%)19.93
PBT Margin (%)2.89
Net PROFIT Margin (%)14.42
Return On Networth / Equity (%)20.18
Return On Networth /Employed (%)25.70
Return On Assets (%)18.60
Total Debt / Equity (X)0.07
Asset Turnover Ratio (%)1.29

Titan Biotech Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual52.03
Total Current Assets Annual72.17
Non Current Assets Annual79.40
Total Shareholders Funds Annual128.44
Total Assets Annual151.57

Titan Biotech Ltd Earning Calls

EPS (INR)

Expected

7.75

Reported

7.74

Surprise

-0.13%

Mar 2024

EPS beaten by -0.13%

Dec 2023

EPS beaten by 0.00%

Sep 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 5, 2024, Titan Biotech Ltd has a market capitalization of 436.49 Cr. Value Research classifies it as a Small-Cap company.
Yes, Titan Biotech Ltd is debt-free with a debt-to-equity ratio of 0.06.
In FY 2023 , Titan Biotech Ltd recorded a total revenue of approximately 164.07 Cr marking a significant milestone in the company's financial performance.
Titan Biotech Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.4% and 0.1% annually, respectively..
Titan Biotech Ltd's current PE ratio is 18.45.
Titan Biotech Ltd's ROCE averaged 26.8% from the FY ending March 2022 to 2024, with a median of 25.2%. It peaked at 31.4% in March 2022, reflecting strong capital efficiency over the period..
Titan Biotech Ltd's latest EBIT is Rs. 32.70 Cr, surpassing the average EBIT of Rs. 30.47 Cr over the 5 years..